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Abstract
Background: Antiretroviral therapy (ART) agents potentially associated with adverse metabolic profiles are
commonly used in low- and middle-income countries. We assessed risk factors for cardiovascular disease
(CVD)-related morbidity and mortality in a cohort of HIV-infected, ART-treated adults in Rio de Janeiro, Brazil.
Methods: Hospital records and mortality data between 2000–2010 were examined for incident CVD-related ICD-10
and Coding of Death in HIV diagnoses among adults ≥18 years old on ART, enrolled in an observational cohort.
Poisson regression models assessed associations between demographic and clinical characteristics and ART agent
or class on CVD event risk.
Results: Of 2960 eligible persons, 109 had a CVD event (89 hospitalizations, 20 deaths). Participants were 65 %
male, 54 % white, and had median age of 37 and 4.6 years on ART. The median nadir CD4+ T lymphocyte count
was 149 cells/mm3. The virologic suppression rate at the end of study follow-up was 60 %. In multivariable models,
detectable HIV-1 RNA prior to the event, prior CVD, less time on ART, age ≥40 at study baseline, nadir CD4+ T
lymphocyte count ≤50 cells/mm3, non-white race, male gender, and a history of hypertension were significantly
associated with CVD event incidence (p < 0.05), in order of decreasing strength. In multivariate models, cumulative
use of tenofovir, zidovudine, efavirenz and ritonavir-boosted atazanavir, darunavir and/or lopinavir were associated
with decreased CVD event risk. Recent tenofovir and boosted atazanavir use were associated with decreased risk,
while recent stavudine, nevirapine and unboosted nelfinavir and/or indinavir use were associated with increased
CVD event risk.
Conclusions: Virologic suppression and preservation of CD4+ T-lymphocyte counts were as important as traditional
CVD risk factor burden in determining incident CVD event risk, emphasizing the overall benefit of ART on CVD risk
and the need for metabolically-neutral first- and second-line ART in resource-limited settings.
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Background
With successful antiretroviral therapy (ART), HIV infec-
tion has been transformed into a chronic disease [1].
Worldwide and in Brazil, AIDS-related morbidity and
mortality has declined, whereas the burden of non-
communicable diseases, such as cardiovascular disease
(CVD), has increased [2–6]. Specifically, CVD risk is up
to two-fold higher among HIV-infected persons com-
pared with HIV-uninfected individuals, even after adjust-
ing for traditional CVD risk factors [7–9]. And, while
higher frequencies of traditional CVD risk factors have
been reported in HIV-infected persons, the impact of
HIV on CVD is most prominent in traditionally low-risk
demographic groups [10–13], suggesting CVD risk in
treated HIV infection may also be mediated by non-
traditional factors.
In Brazil, CVD incidence has risen more rapidly
among HIV-infected persons than the general popula-
tion [14], and hospitalization costs for myocardial infarc-
tions have surpassed those for AIDS-related illnesses
[15]. However, the dual burden of CVD and HIV in low-
and middle-income countries is understudied [16, 17].
Discerning modifiable CVD risk factors in treated HIV
infection may help prevent and treat CVD, reducing
disease burden and health system costs while improving
quality of life.
While ART is critical to successful control of HIV infec-
tion, several observational studies have reported associa-
tions between specific antiretroviral agents and increased
CVD risk [18–24]. Data are conflicting, however, and the
evidence is predominantly derived from U.S. and European
cohorts, whose relevance to low- and middle-income coun-
tries that routinely use ART with poorer metabolic profiles
remains unclear. Understanding whether commonly used
ART regimens may be contributing to CVD risk is a
critical component of long-term HIV management that
may both inform global ART guidelines and improve
clinical practice in resource-limited settings. This
analysis aims to define traditional and HIV-specific risk
factors for CVD in a large cohort of HIV-infected adults
on ART in Rio de Janeiro, Brazil, including whether
specific antiretroviral agents and classes confer additional
risk of CVD morbidity and mortality.
Methods
Study setting and population
The Instituto Nacional de Infectologia Evandro Chagas
(INI) of Fundação Oswaldo Cruz (FIOCRUZ) in Rio de
Janeiro, Brazil is a national public referral center for
HIV/AIDS care. Since 1998, INI has maintained an
observational, longitudinal, open cohort of adults receiv-
ing HIV primary care at their clinic. Complete cohort
procedures have previously been described [25]. Trained
abstractors update the clinical database biannually using
outpatient and inpatient medical records, laboratory re-
sults, and ART usage data. This analysis included all
HIV-infected persons ≥18 years of age with ART expos-
ure (and without a history of Chagas disease) who were
followed in the INI cohort between January 1, 2000 and
December 31, 2010 (Fig. 1).
Study design and outcomes
The primary outcome was a composite endpoint that in-
cluded both hospitalizations and deaths related to CVD,
whichever occurred first. Secondary outcomes included
5,503 patients enrolled in the INI  
cohort from 1987-2013
3,605 patients actively followed in the  
INI cohort during the study period 
(Jan.1, 2000-Dec. 31, 2010) 
2960 patients in INI cohort from Jan  
1, 2000 to Dec 31, 2010 with ART 
exposure
Applied initial exclusion criteria: 
1.Entered cohort after December 31, 2010 (n= 918) 
2. Died prior to January 1, 2000 (n= 529)
3. Last cohort visit before January 1, 2000 (n= 407)
4. Under 18 years of age at cohort enrollment (n= 44)  
Additional exclusion criteria applied:
1. Started ART after end of the study period (n=639) 
2. History of Chagas disease (n=6) 
33 CVD-related deaths (13 occurring  
during a CVD-related hospitalization)
89 CVD-related hospitalizations 
Fig. 1 Study Participant Flowchart
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separate analyses of hospitalization and death outcomes.
Participants were censored after their first hospitalization,
at the time of death, or at end of the study period, which-
ever came first. For both hospitalizations and deaths,
CVD-related events included heart or vascular disease, is-
chemic heart disease, stroke, venous thromboembolism
and pulmonary embolism.
Hospitalizations for CVD-related illnesses were identi-
fied using physician-reported discharge diagnoses linked
to an International Classification of Diseases, Tenth
Revision (ICD-10) code. Clinical diagnoses for cohort
participants hospitalized at INI were retrieved and sys-
tematically checked and validated by two clinicians with
experience in the management of HIV infection. All
diagnoses were classified using ICD-10 codes and then
allocated into 24 categories. From this list, only CVD-
related diagnoses were included in this analysis. For hos-
pitalizations with multiple CVD diagnoses, the primary
cause was determined using a hierarchical approach that
prioritized acute over chronic disease. A complete list of
ICD-10 codes included in this analysis is provided in
Table 1. Of note, 10 % of all hospitalization data (CVD
and non-CVD) were randomly selected for discharge
diagnosis adjudication by a non-treating physician special-
izing in HIV care as a quality control measure. Diagnosis
validation required an objective medical test or other
document, such as a consultation note, discharge sum-
mary, or autopsy report.
For deaths, the “Coding of Death in HIV” (CoDe)
method was used to determine cause of death [3]. This
method requires detailed data collection on the causes
of death and contributing factors by a physician special-
izing in HIV care, applies a uniform coding system and
includes an independent centralized review process per-
formed by two additional HIV specialists [26]. Informa-
tion regarding vital statistics was exhaustively checked
up until December 31, 2010 using patients’ INI medical
charts, through active contact with individuals and
family members, and by linkage with the Rio de Janeiro
State mortality database using a previously validated
algorithm [3, 27]. Only primary, CVD-related causes of
death were included (Table 1), with the exception of six
cases where CVD was determined to be a major con-
tributing factor.
Cumulative and recent exposure to specific antiretro-
viral drugs and classes were calculated [see Additional
file 1 for the complete cohort ART exposure history].
Nucleoside reverse transcriptase inhibitor (NRTI), non-
NRTI (NNRTI), protease inhibitor (PI), and integrase
inhibitor classes were included. No minimum exposure
was required. The cumulative exposure is reported as
the summation of an individual’s time on a given agent
or drug class, up to the end of their study follow-up.
Recent use was defined as any exposure in the 6 months
preceding the event or end of follow-up.
Age at study start was calculated as the difference
between date of birth and the start of the study period.
Race/ethnicity was based on provider report and was
dichotomized as white or non-white. Education was self-
reported and dichotomized as either eight or fewer years
of schooling or greater than 8 years. Presumed HIV
exposure from injection drug use was self-reported,
whereas cocaine use was provider reported. Time since
HIV diagnosis was calculated as the difference between
the self-reported or laboratory documented date of HIV
diagnosis and the study start date. Percent time with
known HIV on ART was calculated by dividing cumula-
tive ART exposure by the difference between the date of
HIV diagnosis and the end of study follow-up. Nadir
CD4+ T lymphocyte count was defined as the lowest
recorded measurement obtained at least 7 days prior to
the end of follow-up, either on or off of ART, and was
categorized as ≤ 50 cells/mm3 or greater. To account for
changing sensitivities of HIV-1 RNA assays over the
study period, virologic suppression was defined as ≤ 400
copies/mL. Viremia copy-years were estimated to quan-
tify cumulative viremia, defined as the number of HIV-1
RNA copies per mL per year, integrated over the number
of years since HIV seroconversion [28].
Traditional CVD risk factors were evaluated until the
end of study follow-up and included diabetes mellitus,
hypertension, dyslipidemia, prior CVD, smoking, chronic
Table 1 Distribution of ICD-10 hospital diagnoses and CoDe
causes of death
ICD-10 Code CVD-Related Hospital Discharge Diagnoses N = 89, n (%)
I82.9 Venous embolism and thrombosis 27 (30.3)
I10 & I11 Hypertension 17 (19.1)
I50.0 Congestive heart failure 12 (13.5)
I63.9 Cerebral infarction 10 (11.2)
I20.9 Angina pectoris 6 (6.7)
I21.9 Acute myocardial infarction 6 (6.7)
J81.0 Pulmonary edema 4 (4.5)
I61.9 Intracerebral hemorrhage 2 (2.3)
I24.8 Acute Ischemic heart disease 1 (1.1)
I26.9 Pulmonary embolism 1 (1.1)
I42.9 Cardiomyopathy 1 (1.1)
I50.1 Left ventricular failure 1 (1.1)
I81.0 Portal vein thrombosis 1 (1.1)
CoDe No. CVD-Related Causes of Death N = 33, n (%)
24 Heart or vascular disease 18 (54.4)
8 Ischemic heart disease 10 (30.3)
9 Stroke 4 (12.1)
12 Lung embolus 1 (3.0)
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kidney disease, and weight. Diabetes mellitus was de-
fined as either prior diagnosis of diabetes mellitus on
treatment, two fasting glucose level ≥126 mg/dL without
symptoms, one fasting glucose level ≥126 mg/dL with
symptoms, or a hemoglobin A1c value of 6.5 or greater.
Dyslipidemia was defined by use of lipid-lowering ther-
apy, low-density lipoprotein (LDL) cholesterol >159 mg/
dL, high-density lipoprotein (HDL) cholesterol <40 mg/dL,
total cholesterol >239 mg/dL, or triglycerides >199 mg/dL.
Similarly, hypertension was defined as prior diagnosis
of hypertension, use of antihypertensive medication,
systolic blood pressure >140 mmHg, or diastolic blood
pressure >90 mmHg. Prior CVD included any history
of stable or unstable angina, cerebrovascular disease, or
myocardial infarction per the medical record. Smoking
history was comprised of a cross-sectional survey of
smoking and self-reported nicotine use. Each partici-
pant was categorized as ever smoker, never smoker, or
unknown. Upon further analysis, persons with an
unknown smoking history (n = 534, 18 %) were found
to have a significantly increased risk of CVD-related
events (data not shown), and were thus reclassified as
ever-smokers to account for any possibility that smok-
ing is causing the outcome of study rather than ART
exposure. History of chronic kidney disease was defined
as provider report or end-stage renal disease requiring
dialysis. A significant proportion of patients were miss-
ing height data for body mass index calculation/obesity
assessment. As such, weight was used as a surrogate
measure for obesity, with the highest weight prior to
the end of follow-up used to create weight tertiles.
Statistical analysis
Study entry was defined as either January 1, 2000 or the
date of cohort enrollment (for participants enrolling
after January 1, 2000). End of follow-up was defined as
the first occurrence of a CVD-related hospitalization,
death due to any cause, or December 31, 2010 (except
when death was analyzed separately and participants
were not censored after hospitalizations). Mortality data
were also gathered from public records.
Descriptive statistics for demographic and clinical vari-
ables were compared using Chi-squared and Wilcoxon
rank sum tests for categorical and continuous variables,
respectively (two-sided α = 0.05). Poisson regression
models using individual-level data explored associations
between traditional and HIV-specific CVD risk factors
(including ART exposure) and risk of cardiovascular
morbidity and/or mortality. Incidence rate ratios for
CVD events were calculated, with person-time defined
as the sum of an individual’s years of study follow-up in-
corporated as an offset. We used a two-step approach to
our multivariate modeling: We initially adjusted for age;
sex; race; education; nadir CD4+ T lymphocyte count;
percent time with known HIV on ART; virologic
suppression in the year prior to the event; history of
diabetes mellitus, hypertension, dyslipidemia, chronic kid-
ney disease, or prior CVD; smoking history; weight; and
calendar year of cohort entry. Covariates with p < 0.10
were retained [see Additional file 2, which details the
process of arriving at the final multivariate regression
model]. ART classes and agents were then added indi-
vidually to the model to estimate additional CVD risk
attributable to ART. Adding ART exposure to the
model obligated exclusion of the percent time with
known HIV on ART variable due to colinearity. Par-
ticipants not on ART in the 6 months prior to an
event were excluded from the analysis of recent ART
exposure.
For the composite endpoint, the model included:
age ≥40 years; male sex; non-white race; nadir CD4+
T lymphocyte count ≤50cells/mm3; percent time with
known HIV on ART; virologic suppression; history of
hypertension, dyslipidemia, or CVD; and calendar year
of cohort entry. Briefly, for hospitalizations, the model
was similar to the composite endpoint model except
that history of diabetes mellitus but not prior CVD
remained significant. For deaths, the model included
age ≥40, ≤ 8 years of schooling, virologic suppression
in the last year, and ≥ 1 metabolic risk factor (diabetes
mellitus, hypertension, untreated dyslipidemia, or chronic
kidney disease).
Missing nadir CD4+ T lymphocyte count (n = 67, 2 %)
and HIV-1 RNA (n = 448, 15 %) data were generated
using multiple imputation, with age, sex, and the percent
time with known HIV on ART as predictors. Missing
weight (n = 91, 3 %) was replaced by median, sex-
specific cohort weight. Missing race (n = 9, 0.3 %) and
education (n = 13, 0.4 %) were replaced with the highest
risk category. Bivariate Poisson regression models dem-
onstrated similar results for multiple imputation versus
exclusion of missing data. Multiple testing was corrected
using the Benjamini-Hochberg method [29, 30]. Stata




INI cohort participants (n = 2960) contributed 16,140
person-years (PY) of follow-up. The median follow-up
was 4.68 years [interquartile range (IQR), 2.34–9.09]).
Baseline characteristics included: median age of 37 years
(IQR, 30, 43), 65 % male, 54 % white, and 53 % had eight
or fewer years of schooling (Table 2). Two percent of
participants reported a history of injection drug use and
9 % reported cocaine use. The median nadir CD4+ T
lymphocyte count was 149 cells/mm3. Median time on
ART was 4.65 years, with 95 % of participants on ART
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Table 2 Characteristics and Cardiovascular Risk Profile of INI Cohort Participants Exposed to ART from 2000–2010
CVD Events VTE events
All study participants No CVD-related events Composite CVD events† CVD-related hospitalization CVD-related death VTE hospitalizations
and death
n n (%) n (%) n (%) n (%) N (%)
Demographic & clinical characteristics 2,960 2,851 (96 %) 109 (4 %) 89 (3 %) 33 (1 %) 30 (1 %)
Median Age at study start (IQR) 37 (30, 43) 36 (30, 43) 42 (35, 51)* 40 (35, 50)* 46 (37, 58)* 36.5 (31, 44)
Age <30 years 710 (24 %) 692 (24 %) 18 (17 %) 14 (16 %) 5 (15 %) 7 (23 %)
30–39 years 1,107 (37 %) 1,080 (38 %) 27 (25 %) 25 (28 %) 6 (18 %)** 11 (37 %)
≥40 years 1,143 (39 %) 1,079 (25 %) 64 (59 %) 50 (56 %) 22 (67 %) 12 (40 %)
Male Gender 1,924 (65 %) 1,849 (65 %) 75 (69 %) 64 (72 %) 21 (64 %) 23 (77 %)
White Race 1,605 (54 %) 1,554 (55 %) 51 (47 %) 40 (45 %) 15 (45 %) 12 (40 %)
≤8 years of Education 1,556 (53 %) 1,487 (52 %) 69 (64 %)** 57 (64 %)** 24 (73 %)** 16 (53 %)
History of IDU 61 (2 %) 58 (2 %) 3 (3 %) 3 (3 %) 1 (3 %) 0 (0 %)
History of Cocaine Use 262 (9 %) 255 (9 %) 7 (6 %) 6 (7 %) 1 (3 %) 2 (7 %)
Time since HIV diagnosis, Median years (IQR) 1.12 (0.13, 5.78) 1.08 (0.13, 5.7) 3.06 (0.24, 6.72)* 3.06 (0.29, 6.5)* 4.7 (0.24, 7.56) 1.35 (0.13, 3.22)
% of time on ART since HIV diagnosis 0.77 (0.47, 0.93) 0.77 (0.47, 0.93) 0.72 (0.43, 0.89) 0.71 (0.42, 0.89) 0.87 (0.52, 0.98) 0.67 (0.41, 0.93)
Median Nadir CD4+ T-cell count, cells/mm3 (IQR) 149 (52, 258) 152 (53, 259) 97 (27, 189)* 88.5 (23, 203)* 104.5 (23.5, 188.5)* 91 (27.5, 182.5)*
Nadir CD4+ T-cell count ≤ 50 cecells/mm3 705 (24 %) 666 (23 %) 39 (36 %)** 33 (37 %)** 13 (39 %)** 11 (37 %)
Virally suppressed year before event 1,771 (60 %) 1,734 (61 %) 37 (34 %)** 29 (33 %)** 14 (42 %)** 9 (30 %)**
Median viremia copy-years, log10 copy x years/mL (IQR) 4.72 (3.99, 5.34) 4.71 (3.98, 5.34) 4.94 (4.33, 5.67) 4.93 (4.28, 5.66)* 4.43 (3.76, 5.06) 5.08 (4.73, 5.82)*
Cardiovascular risk factors
History of Diabetes Mellitus 320 (11 %) 299 (10 %) 21 (19 %)** 18 (20 %)** 5 (15 %) 5 (17 %)
History of Hypertension 792 (27 %) 740 (26 %) 52 (48 %)** 42 (47 %)** 19 (58 %)** 9 (30 %)
History of Dyslipidemiaa 1,487 (50 %) 1,429 (50 %) 58 (53 %) 44 (49 %) 21 (64 %) 11 (37 %)
History of Chronic kidney disease 25 (<1 %) 23 (<1 %) 2 (2 %) 2 (2 %) 1 (3 %) 0 (0 %)
>1 metabolic risk factors for CVD 1,813 (61 %) 1,734 (61 %) 79 (72 %)** 62 (70 %) 29 (88 %)** 17 (57 %)
Prior CVDb 97 (3 %) 81 (3 %) 16 (15 %)** 9 (10 %)** 11 (33 %)** 2 (7 %)
Ever smoked 2,013 (68 %) 1,926 (68 %) 87 (80 %)** 67 (75 %) 33 (100 %)** 21 (70 %)
Median weight kg (IQR)~ 71.3 (62.5, 81.3) 71.6 (62.8, 81.4) 67.6 (60.5, 78.5) 67.5 (60.1, 78.5) 68.6 (60.3, 88) 68.8 (61, 79.2)
Abbreviations: IQR interquartile range, CVD cardiovascular disease
†Composite CVD events include all CVD-related hospitalizations and deaths listed in Table 1
*Rank sum test of comparison of event and non-event groups p < 0.05
**Chi square test of comparison of event and non-event groups p < 0.05
~based on the highest weight recorded prior to the end of follow-up or time of event
aincludes any lab confirmed history of dyslipidemia, hypercholesterolemia, or hypertriglyceridemia, and patients on lipid-lowering drugs














in the 6 months prior to their event/end of follow-up.
Sixty percent of participants had undetectable HIV-1
RNA in the year prior to their event/end of follow-up.
CVD risk factors were highly prevalent, particularly
among participants experiencing CVD events, with 61 %
reporting one or more metabolic risk factors (diabetes
mellitus, hypertension, dyslipidemia, and/or chronic kid-
ney disease). Smoking was the most common risk factor
(68 %), followed by dyslipidemia (50 %), and hypertension
(27 %), with prior CVD present in 3 % of participants.
Forty-three percent of participants with a history of dys-
lipidemia had a documented treatment history, while 72 %
of participants with hypertension received treatment. Of
the available body mass index (BMI) data, only 13 % had a
BMI over 30.
Cardiovascular events
During the study period, 109 persons had a CVD-related
event (89 hospitalizations; 33 deaths, 13 of which occurred
during hospitalization, Table 2), for an overall incidence
rate of 6.75 per 1000 PY (95 % CI: 5.60–8.15). Thirteen
deaths were excluded from the composite endpoint be-
cause the death occurred after a hospitalization/censoring.
Hospitalization and death incidence rates were 5.51 per
1000 PY (95 % CI: 4.48–6.79) and 2.02 per 1000 PY (95 %
CI: 1.43–2.84), respectively. The incidence rates for
thrombotic events and ischemic heart disease were 4.71
per 1000 PY (95 % CI: 3.76–5.90) and 1.80 per 1000 PY
(95 % CI: 1.25–2.59), respectively.
In unadjusted analyses, age ≥40 years, non-white race,
8 years or fewer of schooling, nadir CD4+T lymphocyte
count ≤50 cells/mm3, detectable HIV-1 RNA, smoking,
a history of diabetes mellitus, hypertension, or CVD
and weight in the lowest tertile were associated with in-
cident CVD [see Additional file 3, which details the
crude incidence rate ratios for demographic/clinical
characteristics and cardiovascular risk factors]. Longer
time on ART after HIV diagnosis was significantly protect-
ive. In multivariate analysis, age ≥40 years, non-white race,
nadir CD4+T lymphocyte count ≤50 cells/mm3, detectable
HIV-1 RNA, and a history of hypertension or CVD
remained significant (Fig. 2). Detectable HIV-1 RNA in
the prior year (crude incidence rate ratio (cIRR), 3.99;
95 % CI, 2.61–6.11) and prior CVD (cIRR, 3.99; 95 % CI,
2.35–6.79) were the factors most strongly associated with
a CVD event.
ART exposure
Overall, the cohort had 18,127 PY of cumulative ART
exposure, Fig. 3 maps out the Cohort ART treatment
history. All participants were NRTI-exposed (18,116
PY), 76 % had NNRTI exposure (7411 PY), and 62 %
had PI exposure (9973 PY). Integrase, fusion, and entry
inhibitors were used by a minority of participants (6, 4,
and 1 %, respectively). The most commonly used agents
Fig. 2 Adjusted* incidence rate ratios for associations between cardiovascular disease (CVD) events and patient demographics and clinical
characteristics. *Adjusted for all covariates listed
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were lamivudine (97 %), zidovudine (80 %), tenofovir
(53 %), stavudine (33 %), didanosine (31 %), efavirenz
(67 %), ritonavir-boosted lopinavir (36 %), and ritonavir-
boosted atazanavir (21 %), in keeping with Brazilian
treatment guidelines during the follow-up period.
Impact of ART exposure
After adjusting for traditional and HIV-specific CVD
risk factors, cumulative NRTI exposure was associated
with a 21 % lower CVD event incidence (adjusted IRR
(aIRR), 0.79; 95 % CI, 0.75–0.83, Table 3). Specifically,
cumulative lamivudine, zidovudine, and tenofovir expos-
ure were associated with decreased CVD event incidence.
Cumulative tenofovir exposure had the strongest associ-
ation, with a 40 % decrease in CVD event incidence per
additional year of exposure (aIRR, 0.60; 95 % CI, 0.51–
0.71). Recent stavudine use was associated with a 528 %
increase in CVD event incidence (aIRR, 5.28; 95 % CI
3.18–8.75), whereas recent tenofovir exposure was associ-
ated with a 63 % decreased CVD event incidence (aIRR,
0.37; 95 % CI, 0.24–0.56).
Cumulative NNRTI exposure was significantly associ-
ated with decreased CVD event incidence (aIRR, 0.77;
95 % CI, 0.70–0.85, Table 3), an association driven by
efavirenz use (25 % lower event incidence; aIRR, 0.78;
95 % CI, 0.69–0.87). No effect of cumulative nevirapine
exposure was observed; however, recent nevirapine ex-
posure was associated with an overall increased CVD
event incidence (aIRR, 3.07; 95 % CI, 1.44–6.53). Neither
recent NNRTI class nor recent efavirenz exposure were
significantly associated with CVD event incidence.
Cumulative PI exposure was associated with a 12 %
decreased CVD event incidence (aIRR 0.88; 95 % CI,
0.83–0.93). This effect did not change significantly when
high-dose ritonavir exposure was excluded (Table 3).
Each additional year of exposure to ritonavir-boosted
lopinavir (aIRR, 0.81; 95 % CI, 0.71–0.92), atazanavir
(aIRR, 0.60; 95 % CI, 0.45–0.81), and darunavir (aIRR,
0.65; 95 % CI, 0.45–0.95) was associated with decreased
CVD event incidence (19, 40, and 35 %, respectively).
Recent ritonavir-boosted atazanavir exposure was associ-
ated with a 60 % decreased CVD event incidence (aIRR,
0.40; 95 % CI, 0.21–0.76), whereas recent high-dose rito-
navir (aIRR, 2.67; 95 % CI, 1.30–5.47), unboosted nelfi-
navir (aIRR, 5.32; 95 % CI, 2.60–10.88) and unboosted
indinavir (aIRR, 10.22; 95 % CI, 4.63–22.53) exposure
were associated with increased CVD event incidence.
When hospitalizations and deaths were analyzed
separately, associations with ART use were similar (see
Additional file 4, which demonstrate the crude and
adjusted incidence rate ratios for cardiovascular hos-
pitalizations and deaths by exposure to specific ART
agents). Sensitivity analysis excluding venous thrombo-
embolism and pulmonary embolism from the primary
outcome variable did not significantly change results
[see Additional file 5 for further discussion of and re-
sults from the sensitivity analysis]. Additionally, neither
excluding participants with prior CVD nor restricting
the PI exposure analysis to participants with PI and
NNRTI exposure significantly altered results, although
traditional CVD risk factors became more prominent
when prior CVD was excluded (data not shown). After
Fig. 3 INI Cohort ART Treatment History
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Table 3 Crude and Adjusted a Incidence Rate Ratios for CVD Events by Exposure to Specific Antiretroviral Drugs
Cumulative exposure Recent exposure
N cIRR 95 % CI P aIRR 95 % CI P cIRR 95 % CI P aIRR 95 % CI P
ART 109 0.85 0.81–0.89 <0.001 0.79 0.75–0.83 <0.001 – – – – – –
NRTI 109 0.85 0.81–0.89 <0.001 0.79 0.75–0.83 <0.001 – – – – – –
Lamivudine 105 0.80 0.75–0.84 <0.001 0.76 0.72–0.81 <0.001 0.56 0.30–1.05 0.069 0.71 0.37–1.36 0.31
Zidovudine 93 0.86 0.81–0.91 <0.001 0.83 0.78–0.89 <0.001 1.27 0.86–1.89 0.23 1.34 0.90–2.00 0.15
Tenofovir 39 0.64 0.55–0.75 <0.001 0.60 0.51–0.71 <0.001 0.42 0.28–0.64 <0.001 0.37 0.24–0.56 <0.001
Stavudine 56 0.97 0.90–1.05 0.50 0.96 0.88–1.04 0.30 6.13 3.91–9.60 <0.001 5.28 3.18–8.75 <0.001
Didanosine 51 0.95 0.87–1.04 0.29 0.91 0.82–1.02 0.10 1.47 0.68–3.17 0.32 1.50 0.68–3.27 0.32
Emtricitabine 5 0.78 0.49–1.25 0.30 0.83 0.51–1.36 0.46 2.29 0.73–7.23 0.16 2.61 0.81–8.43 0.11
Abacavir 6 0.70 0.43–1.14 0.15 0.63 0.36–1.11 0.11 0.97 0.24–3.94 0.97 0.70 0.17–2.86 0.62
Zalcitabine 10 1.01 0.66–1.55 0.96 0.90 0.57–1.41 0.64 – – – – – –
NNRTI 79 0.76 0.69–0.83 <0.001 0.77 0.70–0.85 <0.001 1.05 0.72–1.55 0.79 1.42 0.94–2.13 0.097
Efavirenz 67 0.75 0.67–0.84 <0.001 0.78 0.69–0.87 <0.001 0.90 0.60–1.34 0.59 1.25 0.81–1.93 0.31
Nevirapine 31 0.92 0.81–1.05 0.24 0.91 0.78–1.05 0.20 2.46 1.20–5.06 0.014 3.07 1.44–6.53 0.004
PI 79 0.92 0.88–0.96 0.001 0.88 0.83–0.93 <0.001 1.20 0.80–1.81 0.37 0.79 0.50–1.23 0.29
PI (without high dose RTV) 78 0.92 0.87–0.96 <0.001 0.87 0.83–0.92 <0.001 1.16 0.77–1.73 0.48 0.75 0.48–1.17 0.20
Ritonavir 35 0.91 0.78–1.05 0.20 0.84 0.71–1.01 0.061 4.05 2.05–8.03 <0.001 2.67 1.30–5.47 0.007
Lopinavir/
Ritonavir
41 0.86 0.76–0.96 0.009 0.81 0.71–0.92 0.001 1.20 0.79–1.84 0.40 0.90 0.58–1.39 0.64
Atazanavir + Ritonavir 13 0.60 0.45–0.79 <0.001 0.60 0.45–0.81 0.001 0.36 0.19–0.69 0.002 0.40 0.21–0.76 0.006
Darunavir + Ritonavir 6 0.71 0.50–1.02 0.067 0.65 0.45–0.95 0.027 0.64 0.28–1.46 0.29 0.47 0.20–1.09 0.08
Nelfinavir without booster 28 0.97 0.87–1.09 0.66 0.96 0.84–1.09 0.50 7.77 4.05–14.91 <0.001 5.32 2.60–10.88 <0.001
Indinavir without booster 39 1.05 0.95–1.16 0.35 1.00 0.89–1.11 0.98 11.56 5.84–22.90 <0.001 10.22 4.63–22.53 <0.001
Saquinavir + Ritonavir 4 0.55 0.15–2.0 0.37 0.47 0.11–2.12 0.33 1.63 0.23–11.68 0.63 1.05 0.14–7.58 0.97
Saquinavir without booster 24 0.90 0.71–1.13 0.35 0.82 0.62–1.08 0.15 3.96 1.46–10.76 0.007 2.07 0.71–6.00 0.18
Amprenavir + Ritonavir 3 1.55 0.82–2.93 0.18 1.37 0.66–2.85 0.39 – – – – – –
Amprenavir without booster 4 0.85 0.42–1.73 0.66 0.64 0.28–1.49 0.30 9.62 1.34–68.95 0.024 3.88 0.52–28.89 0.19
Integrase Inhibitor 4 0.82 0.53–1.28 0.39 0.78 0.50–1.22 0.28 0.62 0.23–1.69 0.35 0.54 0.20–1.49 0.24
Abbreviations: CVD cardiovascular disease, N number of participants with a CVD-related event exposed to the specific agent, cIRR crude incidence rate ratio, CI confidence interval, P p-value, ART combined antiretroviral
therapy, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-NRTI, PI protease inhibitor, RTV ritonavir
aFinal model was adjusted for specific ART agent or class; age ≥40 years; male sex; non-white race; nadir CD4+ T lymphocyte count ≤50 cells/mm3; virologic suppression; history of hypertension, dyslipidemia, or CVD;














adjustment for multiple testing, cumulative darunavir
use was the only result to lose significance.
Discussion
We sought to clarify the link between traditional and
HIV-specific risk factors and cardiovascular morbidity and
mortality in a large, well-characterized cohort of HIV-
infected adults on ART in a middle-income country. We
observed a significant burden of traditional CVD risk fac-
tors compared with the general Brazilian population [31].
Notably, our cohort was young relative to previously-
studied cohorts, with 61 % under 40 years of age [22, 23].
Similarly, although age 40 and over was associated with
increased CVD event risk in multivariate analysis, 41 % of
events occurred in persons less than 40 years of age (IR,
4.46 per 1000 PY; 95 % CI, 3.33–5.98). Additionally, 61 %
of participants had at least one traditional CVD risk
factor. While these rates are comparable to other stud-
ies of HIV-infected persons in Brazil and Latin America
[32, 33], the risk factor burden for age is greater than
previously observed CVD risk factor frequencies in the
United States and Europe [22, 24, 34, 35].
HIV-specific risk factors were more strongly associated
with incident CVD morbidity and mortality than trad-
itional CVD risk factors, including nadir CD4+ T
lymphocyte count ≤50 cells/mm3 and detectable HIV-1
RNA in the year prior to the event. These factors
remained independently associated with incident CVD
after controlling for time on ART, consistent with litera-
ture citing low nadir CD4+ T lymphocyte count and on-
going HIV replication as risk factors for CVD [36–39],
but countering the belief that traditional CVD risk fac-
tors account for the majority of CVD risk in the setting
of HIV infection [40]. Even though ART is universally
available through Brazil’s public health system at no cost,
late diagnosis remains a problem, as evidenced by low
nadir CD4+ T lymphocyte counts [41]. Moreover, viro-
logic suppression rates were sub-optimal at 60 %, and
poorer adherence may be related to the toxicity of the
available first and second line regimens [42].
Low nadir CD4+ T lymphocyte count and ongoing
HIV replication are linked to chronic immune activation
and inflammation in HIV-infected persons, contributing
to atherosclerosis development via HIV-mediated endo-
thelial injury and the promotion of a pro-thrombotic
state [43]. Even though venous thromboembolism may
traditionally be viewed as a distinct pathophysiologic
entity from atherosclerotic CVD, there is an increasing
body of evidence suggesting that patients with unpro-
voked venous thromboembolism are at a higher risk of
arterial cardiovascular events than matched controls,
and that venous and arterial thrombosis may instead be
“two aspects of the same disease” [44–47]. The seem-
ingly bi-directional relationship between coagulation and
inflammation becomes significant in HIV infection since,
in addition to a two-fold increased risk of myocardial in-
farction (MI), patients infected with HIV are at a two-to-
ten-fold increased risk for a venous thromboembolic
event [48–51]. Interestingly, levels of pro-thrombotic
monocyte and tissue factor activation in HIV-infected
persons with uncontrolled viremia mirror levels in HIV-
uninfected persons experiencing acute coronary syndrome
[52]. And, although some biomarkers of inflammation and
immune activation decrease significantly with ART-
induced virologic suppression, residual monocyte/macro-
phage activation persists and independently predicts
mortality and disease burden in this population [53–59].
In light of the potential pathophysiologic link between
these disease states, particularly in the chronic inflamma-
tory state of HIV infection, the inclusion of thrombo-
embolic events is a unique strength of this study.
We also examined associations between ART exposure
during the study period and the risk of CVD events.
Cumulative NRTI, NNRTI, and/or PI exposure were as-
sociated with a 12–23 % decreased CVD event incidence
per additional year of exposure. Cumulative tenofovir
and atazanavir use had the strongest associations, and
these associations persisted both when hospitalizations
and deaths were analyzed separately and when recent
use was examined. In contrast, recent stavudine, nevira-
pine, high-dose ritonavir, unboosted nelfinavir, and
unboosted indinavir exposure were associated with in-
creased CVD event incidence. Neither cumulative nor
recent abacavir exposure were significantly associated
with CVD event incidence, although only 7 % of partici-
pants had abacavir exposure due to the high cost of
HLA B5701 testing and the lack of generic formulations
in Brazil. Our findings are in contrast to prior observa-
tional studies that detected an association between PI
use and CVD [19, 23, 60–62]. Additionally, the D:A:D
study group reported an increased risk of MI associated
with cumulative indinavir and lopinavir-ritonavir ex-
posure, as well as recent abacavir and didanosine ex-
posure [20, 22]. Since then, results regarding CVD risk
and abacavir and other ART exposure have been
conflicting [24, 34, 35, 63, 64]. Interestingly, recently
published data from the Swiss Cohort suggests that risk
from recent abacavir exposure may confer cumulative
risk, but only for a limited period, with exposure during
the past six to 36 months causing the greatest increase
in risk [65]. Coupled with their finding of a rapid early
harmful effect for didanosine followed by a protective
effect, these results suggest that there may be different
processes mediating ART-associated CVD risk that are
drug-specific [65].
This cohort differs from previously studied U.S. and
European cohorts in that it is from a developing country
setting with universal access to ART, but with a limited
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choice of agents that differs from what is commonly
used in higher income settings. Until 2013, a zidovudine
(AZT) backbone was the standard first line therapy,
typically with lamivudine. Alternatives to AZT were
didanosine or tenofovir. Abacavir was, and remains,
rarely used due to its higher cost relative to other
NRTIs, as is the case for emitricitabine. First line ART
remains primarily NNRTI-based, with efavirenz being
the preferred NNRTI, although PI use is allowed and com-
monly used as second line therapy. Lopinavir/ritonavir is
the first choice PI, and atazanavir/ritonavir can be used as
an optional PI. Third line and salvage therapy are also
available and mostly based on agents such as darunavir,
raltegravir, etravirine and enfuvirtide. The availability of
such drugs has been expanded along the years, according
to their availability in the market and their affordability in
the Brazilian public health system. These results stress the
importance of enhancing access to ART regimens with
improved metabolic profiles as first and second line treat-
ment in low- and middle-income settings, especially in the
context of advanced HIV disease.
This study has several limitations, most significantly its
observational design, which limited our ability to control
for unknown sources of confounding and bias. Known
sources of confounding were controlled for whenever
possible, and treatment selection bias was minimized as
physicians must prescribe in accordance with algorithmic
Brazilian HIV treatment guidelines. We could not fully
account for the effects of chronic kidney disease as time-
updated glomerular filtration rates were not available.
BMI was not available for all participants, and standard-
ized screening was not present for family and social his-
tory variables, including substance use. Although we were
not able to control for obesity due to missing BMI data,
we observed a trend towards increased risk of CVD events
with lower BMI (data not shown), and this trend remained
consistent when weight tertiles were used. We were not
able to control for concurrent ART use in our models
given the limited number of events, and we were
underpowered to fully discern sex differences in CVD
risk (although our analysis included 35 % women). We
only captured hospitalizations at the INI hospital,
which could underestimate CVD morbidity in this
cohort. However, as one of the largest public health
reference centers for HIV care and research in Rio de
Janeiro, it is also the hospital that HIV-infected persons
experiencing serious hospitalizations are referred to, min-
imizing missing data due to hospitalizations outside of
INI. It is important to note that the hospital is located
within the same campus as ambulatory care and that pa-
tients’ records are linked by a unique ID. While only 10 %
of the hospitalizations were randomly reviewed for adjudi-
cation, given the high observed agreement, no further
quality control comparisons were conducted. Similarly,
given that the Rio de Janeiro State mortality database
routinely tracks vital statistics on all residents, the loss to
follow up in this cohort is expected to be minimal. Lastly,
evaluating the contribution of specific ART agents and
classes to CVD risk is complicated by the fact that regi-
mens typically include three or more agents, regimen
changes are common, and ART use is inherently linked to
virologic suppression. Important strengths of this study
include the well-characterized nature of this cohort, its di-
versity of race and sex, use of both hospitalization and
death data, and the characterization of acute CVD events
beyond myocardial infarctions.
Conclusions
Our data are the first to evaluate the association be-
tween HIV infection and ART exposure with CVD risk
in Latin America. CVD in treated HIV infection is an
increasingly prevalent comorbidity whose origins are
not fully understood; however, traditional CVD and
HIV-specific risk factors must both be considered as
prevention and treatment strategies are developed. We
found that traditional, virological and immunological
risk factors all strongly predicted incident CVD, with
ART use and subsequent virologic suppression gener-
ally associated with a decreased incidence of CVD
events. Our findings support other literature suggesting
an overall benefit of ART (and subsequent virologic
suppression) on CVD risk [66–69]; however, our data
are unique in that they document CVD events occur-
ring in a young population with a high traditional
CVD risk burden, supporting resource allocation to-
wards risk factor reduction efforts at all ages to pre-
vent CVD events in HIV-infected persons. Our data
also highlight the importance of early HIV diagnosis
and treatment, as well as the need for availability of
metabolically-neutral first- and second-line ART in
resource-limited settings.
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